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PREFACE 
 
November 6, 2012 
San Francisco, California  
 
Dear Colleagues,  
 
Welcome to the facioscapulohumeral muscular dystrophy FSHD International Research 
Consortium 2012.  Thank you for coming.  Thank you for participating.  Thank you for 
sharing and collaborating.  The goal of this meeting is to create synergy to facilitate more 
progress on FSHD.  It is essential for the entire community to work together at every level 
to communicate clearly on programs, developments and needs.  We hope this meeting 
helps to this end. 
 
In the interest of time, please emphasize new data and ideas.  As you present, please try 
to address which of the four major priority areas identified last year (see below) your 
work has impact on.   Please keep platform presentations to 20 minutes including 5-10 
minutes for questions and answers.   Poster presenters will have two to three minutes to 
highlight their work by PowerPoint presentation.  Platform speakers please consider 
bringing a poster as well.   
 
Initially we will revisit last year’s four areas that we previously identified as a group as 
priorities for FSHD.  Across the day we will discuss what we have achieved, where we 
need to focus, and what are the lacunae?  By the end of the day we should be able to 
identify what and if any of these should change or be modified, and if new areas should 
be considered.   
 
This meeting is organized by the FSH Society and sponsored by Association Française 
Contre les Myopathies (AFM), the FSH Society, the FSHD Global Research Foundation, the 
Muscular Dystrophy Association (MDAUSA), the U.S. DHHS NIH Eunice Kennedy Shriver 
NICHD Sen. Paul D. Wellstone BBRI FSHD Muscular Dystrophy Cooperative Research 
Center, and Sanofi-Genzyme.  It is truly a pleasure to come together to accelerate 
solutions for FSHD.  Thank you for your extraordinary efforts and hard work on behalf of 
patients and their families! 
 
 Sincerely,  
 
Dr. Rabi Tawil, M.D. 
University of Rochester School of Medicine, Rochester, New York 
 
Silvère van der Maarel, Ph.D. 
Leiden University Medical Center, Leiden, the Netherlands  
 
Daniel Paul Perez 
FSH Society, Inc., Watertown, Massachusetts 
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Tuesday, November 6, 2012 
 
 
 
Registration &  
       Breakfast  7:30a.m.-8:00 
 
Welcome  8:00-8:05 
 
Review of 2011  8:05-8:30 Review of 2011 Priorities as Stated by FSHD Research 
     Moderator: Louis M. Kunkel, Ph.D. 
  
Platform Session 1 8:30-9:30 Clinical, Physiological and Diagnostic Studies (3x20 minutes) 
 
Flex Time for Discussion 9:30-9:45 
 
Platform Session 2 9:45-10:45 Disease Genes and Genetic Studies (3x20 minutes) 
 
Flex Time for Discussion 10:45-11:00 
 
Poster Introductions 11:00-11:30 Poster Introductions (3 minutes each) 
 
Free assembly session 11:30-12:00 [collect and have Lunch] 
 
Platform Session 3 12:00-1:00 Molecular Studies (3x20 minutes) 
 
Flex Time for Discussion 1:00-1:15  
 
Platform Session 4 1:15-2:15 Therapy (3x20 minutes) 
 
Flex Time for Discussion 2:15-2:30 
 
Free Assembly Session 2:30-3:00  
 
Moderated Discussion 3:00-4:00 Define 2012/2013 research priorities, future directions, etc. 
Moderators:   Alexandra Belayew, Ph.D., Yi-Wen Chen, Ph.D., 
Rabi Tawil, M.D., and Silvere van der Maarel, Ph.D. 
 
Adjourn     4:00p.m. 
 
 
 
 
The FSH Society, Inc. (Facioscapulohumeral Muscular Dystrophy) is an independent, non-profit 501(c)(3) and 
tax-exempt U.S. corporation organized to address issues and needs specifically related to 
facioscapulohumeral muscular dystrophy (FSHD). Contributions and financial donations are acknowledged 
for tax purposes.  All inquiries should be addressed to: FSH Society, Inc., Daniel Paul Perez, phones: (617) 
658-7811 and (781) 275-7781, fax: (781) 275-7789, e-mail: daniel.perez@fshsociety.org, website: 
http://www.fshsociety.org
NOTES ON TALKS AND POSTERS  
 
   First Author Presenting Author Topic   Session 
Platform Session 1 
Chair:  Rabi Tawil, M.D. 
 
8:30-8:50 a.m.   Janssen   Padberg   MRI   Clinical and DX Studies 
8:50-9:10 a.m.   Lassche   Lassche    Sarcomere   Clinical and DX Studies 
9:10-9:30 a.m.  Lunt   Lunt   Clinical Proforma  Clinical and DX Studies 
 
Platform Session 2 
Chair:  Silvere van der Maarel, Ph.D.  
 
9:45-10:05 a.m.   Lemmers Lemmers  FSHD2/FSHD1B  Disease Genes 
10:05-10:25 a.m.  Ricci   Tupler   Prognosis  Disease Genes 
10:25-10:45 a.m.  Sacconi  Sacconi   FSHD2/FSHD1B  Disease Genes 
 
Poster Introductions  
Chair:  Daniel G. Miller, M.D., Ph.D.  
 
11:00-11:03 a.m.  Boyar  Strom/Boyar  Diagnostics  Poster 
11:03-11:06 a.m.  Domire   Harper/Wallace  DUX4   Poster 
11:06-11:09 a.m.  Gundesli Gundesli  Inheritance  Poster 
11:09-11:12 a.m.  Janssen  Padberg   MRI   Poster    
11:12-11:15 a.m.  De Morree   De Morree  mRNA Processing  Poster  
11:15-11:18 a.m.  Pandey    Pandey/YW Chen  Autophagy  Poster  
11:18-11:21 a.m.  Rahimov Kunkel/Rahimov  Biomarkers  Poster  
11:21-11:24 a.m.  Scionti  Tupler/Scionti  Population  Poster 
11:24-11:27 a.m.  Tassin  Belayew/Tassin  DUX4/DUX4c  Poster  
11:27-11:30 a.m.  Whittington Lunt   Diagnostics  Poster    
 
Platform Session 3 
Chairs:  Louis Kunkel, Ph.D.  
 
12:00-12:20 p.m.  Harafuji  YW Chen  miR411   Molecular Studies  
12:20-12:40 p.m.  Roche   Roche   Fetal FSHD  Molecular Studies  
12:40-1:00 p.m.  Wallace   Wallace   DUX4 Promoters  Molecular Studies  
 
Platform Session 4 
Chairs:  Scott Q. Harper, Ph.D. 
 
1:15-1:35 p.m.   Block   Block   DUX4   Therapy  
1:35-1:55 p.m.   Bosnakovski Bosnakovski  DUX4   Therapy 
1:55-2:15 p.m.   Ansseau  Belayew/Ansseau AONs   Therapy 
 
Posters  [ Boyar  Strom/Boyar     Poster 
   Domire   Harper/Wallace     Poster 
   Gundesli Gundesli     Poster 
   Janssen  Padberg/Lassche     Poster   
   Kazakov  Kazakov      Poster 
De Morree   De Morree     Poster  
Pandey    Pandey/YW Chen     Poster  
   Rahimov Kunkel/Rahimov     Poster  
   Scionti  Tupler/      Poster 
   Tassin  Belayew/Tassin     Poster  
   Whittington Lunt      Poster  ] 
 
Abstract numbers that are followed by a “[P]” in abstracts that follow denote poster presentation
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THE TOP FOUR AREAS IDENTIFIED AS A PRIORITY FOR FSHD BY THE WORLD WIDE SCIENTIFIC  
COMMUNITY IN NOVEMBER 2011 
 
The international FSHD clinical and research community recently came together at the DHHS NIH 
NICHD Boston Biomedical Research Institute Senator Paul D. Wellstone MD CRC for FSHD. Almost 95 
scientists working on FSHD globally met at the 2011 FSH Society FSHD International Research 
Consortium, held November 7-8, 2011. 
 
The summary and recommendations of the group state that given the recent developments in our 
definition of FSHD and the potential that within one to two (1-2) years, evidence-based intervention 
strategies, therapeutics, and trials being planned and conducted. Our immediate priorities should be to 
confirm the DUX4 hypothesis, if valid then understand normal DUX4 function, and finally, 
understanding the naturally occurring variability should allow us to manipulate the disease in our 
favor. We need to be prepared for this new era in the science of FSHD, by accelerating efforts in the 
following four areas: 
 
1. Genetics / epigenetics 
 
It is now broadly accepted that the disregulation of the expression of D4Z4 / DUX4 plays a 
major role in FSHD1 and FSHD2. Additional FSHD (modifier) loci are likely to exist. 
 
FSHD molecular networks. The relaxation of the chromatin structure on permissive 
chromosome 4 haplotypes leads to activation of downstream molecular networks. Importantly, 
the upstream processes – triggering of activation – are equally important. 
Detailed studies on these processes are crucial for insight in the molecular mechanisms of FSHD 
pathogenesis and may contribute to explaining the large intra- and interfamily clinical 
variability. Importantly such work may lead to intervention (possibly also prevention) targets. 
 
Additional FSHD genes. FSHD2 is characterized by hypomethylation of D4Z4 on chromosome 4 
as well as chromosome 10. This also leads to bursts of DUX4 expression. Identification of the 
responsible factor (gene) and molecular mechanisms is of utmost importance. This work will be 
facilitated by the recruitment of additional families. Also other genes need to be considered 
that may give rise to FSHD-like phenotypes. These include, but are not limited to, CAPN3 and 
the FAT1 gene that was recently suggested to be involved in FSHD. 
 
2. Clinical trial readiness 
 
It is now broadly accepted that disregulation of the expression of D4Z4 / DUX4 is at the heart of 
FSHD1 and FSHD2. This finding opens perspectives for intervention along different avenues. 
 
Clinical Trial Readiness. Intervention trials are envisaged within the next several years. The 
FSHD field needs to be prepared for this crucial step. To design and coordinate this important 
translational process, it was envisaged to install an international task force Clinical Trial 
Readiness (FSHD-CTR), with Dr Rabi Tawil as leader. The FSHD-CTR needs to be a 
7 
FSH Society, Inc. FSHD International Research Consortium & Research Planning Meeting.  November 6, 2012 ©FSH Society 2012 
 
multidisciplinary group, including members with expertise, not only in FSHD but also, in trial 
design and execution, statistics, (non-invasive) biomarkers etc. Important issues are: 
 
Natural history 
Homogeneous clinical criteria 
Biobanks, biomarkers, etc. 
Reliable outcome measures 
Patient registries 
 
Biomarkers. Sensitive biomarkers are needed to monitor intervention: they might also 
improve diagnosis. Important to consider biomarkers established from easily accessible 
sources like blood. Non-invasive methods like imaging needs further attention. 
Quantitative muscle function methods are instrumental as are patient-reported indicators. 
 
3. Model systems 
 
There are a plethora of cellular and models, based on different pathogenic (candidate gene) 
hypotheses.  Moreover, the phenotypes are very diverse and often difficult to compare with 
the human FSHD phenotype. 
 
FSHD Model Data Base. The importance of a systematic database was recognized. This data 
base should contain detailed information on the molecular characteristics of the model 
(design and phenotype). Particular emphasis should be paid to the muscle pathology. Non-
muscle phenotypes – described also in FSHD patients deserves attention. 
 
Human pathology and bio-banking. Importantly, this data base should also contain well 
documented muscle pathology data of patients – astonishingly difficult to find in the 
literature. 
 
Human cellular resources continuously deserve attention. Recent progress in ES-cell 
technology, including iPS lines, allows for inter-group distribution and dedicated molecular 
(epi)genetic studies. 
 
4. Sharing 
 
Timely sharing of information and resources remains a critical contributor to the progress in 
the field. There are several initiatives that create large repositories of data and resources, e.g. 
NIH Wellstone MD CRC FSHD and R.T. Fields Center. Their websites should be used for sharing 
of information (e.g. protocols, guide to FSHD muscle pathology (images), model systems, 
contact information), reagents, and resources. 
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1. 
 
Evaluation of new antisense oligomers targeting the DUX4 mRNA as a therapeutic strategy for FSHD 
 
Ansseau E.*1, Vanderplanck C.*1, Wallace LM.2, Tassin A.1, Domire JS.2, Guckes SM.2, Yip C.1, 
Laoudj-Chenivesse D.3, Coppée F.1, Wilton S.4, Harper SQ.2 and Belayew A.1 
 
*Contributed equally to this study  
1Laboratory of Molecular Biology - University of Mons, 7000 Mons, Belgium 
2Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, 
43205 USA 
3INSERM U1046, CHU A. de Villeneuve, 34295 Montpellier, France  
4Molecular Genetic Therapy Group, University of Western Australia, Nedlands, 6009 Western Australia, 
Australia. 
 
There is now compelling evidence that expression of DUX4 is implicated in the pathogenesis of FSHD. 
The expertise of Prof. Wilton's group in antisense oligomer (AO) design and induced exon skipping in 
Duchenne muscular dystrophy (DMD) has led to a collaboration with our group to knockdown DUX4 
expression in an in vitro model of FSHD [1]. Several AOs designed to target exons 2 and 3 of pLAM for 
exclusion from the DUX4 mRNA, synthesized as 2'-O-methyl on a phosphorothioate backbone, were 
able to suppress DUX4 protein expression in primary human myoblast cultures. The effect was specific, 
although some of the AOs were more efficient than others, in that they suppressed DUX4 expression at 
lower transfection concentrations and, more importantly the AOs did not alter expression of the 
homologous DUX4c protein. While all the AOs suppressed DUX4 expression, the ones targeted to exon 
3 appeared to be more effective. 
 
 Empirical AO optimization can influence dystrophin exon skipping efficiency significantly [2] and select 
AO combinations can greatly increase specificity of exon skipping in DMD [3,4]. In a similar strategy we 
have tested AO cocktails and also 2 additional AOs targeting other features of the DUX4 mRNA that 
could affect its splicing or polyadenylation. As expected, the AO cocktails and new AOs suppressed 
endogenous DUX4 mRNA and protein expression as well as FSHD markers in FSHD primary myotubes. 
Moreover, the DUX4 inhibition prevented development of the atrophic myotube phenotype.       
The 3 most effective AO sequences were prepared as “vivo-morpholino” to test them in a mouse 
model. In collaboration with Prof. Scott Harper’s group, we performed a preliminary experiment to test 
those AOs in an alternative FSHD model in which recombinant AAV (adeno-associated virus) vectors 
expressing DUX4 were injected in the tibialis anterior muscle of mice [5].  After co-injection with one of 
these AOs we observed a decrease in the amount of DUX4 mRNA.  
 
These experiments will be repeated to confirm a putative efficiency of these AOs in vivo. 
 
References: 
 
[1]Vanderplanck C, Ansseau E, Charron S, Stricwant N, Tassin A, et al. PLoS One. 2011;6(10):e26820. 
[2]Harding PL, Fall AM, Honeyman K, Fletcher S, Wilton SD. Mol Ther 2006; 15: 157-66. 
[3]Mitrpant C, Fletcher S, Iversen PL, Wilton SD. J Gene Med 2009; 11: 46-56. 
[4]Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S, Wilton SD. BMC Mol Biol 2007; 8: 57. 
[5]Wallace LM, Garwick SE, Mei W, Belayew A, Coppee F, Ladner KJ, et al. Ann Neurol 2011; 69: 540-52. 
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2. 
 
Myotubes generated from FSHD-muscle biopsies undergo DUX4-dependent apoptosis and enable 
the identification of chemicals and pathways that reduce DUX4 expression 
 
Gregory J. Block1,4, Divya Narayanan1,4, Amanda M. Amell1,4, Lisa M. Petek1,4, Kathryn Davidson2,4, Rabi 
Tawil5, Randall Moon2-4, and Daniel G. Miller1,4 
 
1Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington 
2Department of Pharmacology, University of Washington School of Medicine, Seattle, Washington 
3Howard Hughes Medical Institute, University of Washington School of Medicine, Seattle, Washington 
4Institute for Stem Cell and Regenerative Medicine, University of Washington School of Medicine, 
Seattle, Washington 
5University of Rochester Medical Center, Rochester New York  
 
Cultured myoblasts from FSHD-muscle biopsies express DUX4 in 0.01% of nuclei and grow and 
differentiate normally, thereby making the identification of pathways that regulate DUX4 and disease 
progression challenging. Using a novel method of myoblast differentiation, we demonstrate that 
primary FSHD-myotubes undergo apoptosis initiated by myotube-specific activation of DUX4. Chemical 
inhibitors of apoptosis prevent myotube death; however, we have also identified key cellular pathways 
that reduce DUX4 expression and concomitant myotube death.  Finally, we demonstrate that genetic 
pathways thought to alter chromatin structure of D4Z4 also modify DUX4 expression levels and 
myotube viability, suggesting that these genes may modify disease severity and penetrance in FSHD 
patients.  Therefore, cultured myotubes from FSHD patients are an excellent preclinical platform to 
identify compounds, signaling pathways, and chromatin modifiers involved in FSHD. 
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3.  
 
Small molecules with antioxidative properties are prevalent DUX4 inhibitors within HTS library 
 
Darko Bosnakovski1,2, Si Ho Choi2, Erik Toso2 , Michael A. Walters3, Jessica M. Strasser3 and Michael 
Kyba2 
 
1University Goce Delcev - Stip, Faculty of Medical Sciences, Krste Misirkov b.b., 2000 Stip, R. Macedonia 
2Lillehei Heart Institute, Department of Pediatrics, University of Minnesota, Minneapolis, Minnesota, 
55014 
3Institute for Therapeutics Discovery and Development, College of Pharmacy, University of Minnesota, 
Minneapolis, Minnesota, 55014 
 
DUX4 has emerged as the key molecular target in Facioscapulohumeral Muscular Dystrophy (FSHD). 
We have shown that DUX4 induces cell toxicity in skeletal muscle at high levels of expression while at 
low levels it interferes with differentiation and myogenic gene expression related to the FSHD 
molecular phenotype. A first step towards developing a targeted therapy for FSHD is to discover 
chemical compounds that inhibit the activity of the DUX4 protein. We have taken advantage of the 
conditional toxicity of DUX4-inducible myoblasts to develop a small molecule screening platform for 
identifying inhibitors of DUX4.  The assay was based on rapid toxicity of high level DUX4 expression 
which leads to myoblast death within 24 hours. High throughput screening (HTS) of more than 200.000 
small molecules as a part of UT Southwestern HTS compound library was done identified 
approximately 700 compounds with significant rescue effect. To identify direct inhibitors, we have 
conducted serial follow up assays, including secondary screens for interference with the conditional 
gene expression system, reversion of toxicity in other DUX4-expressing cell types (fibroblast, human ES 
cells) and protection against other cell death-inducing signals.  
 
We are currently working with a subset of 100 purchased compounds.  These were selected based on 
pharmacological desirability analyses and the presence of multiple related compounds that form a 
chemical series within the hit set. While the majority of hits are singlets, our analysis identified 46 
distinct chemical series. Rescreening these purchased compounds demonstrated Almost all of the 
purchased compounds demonstrated some degree of protection from DUX4-induced cell death 
indicating the success of the primary screen.  Follow up screens indicated that the majority of these 
hits were also acting independently of the dox-inducible system.  Interestingly, further analyses 
revealed that a very large subset of the selected compounds confer protection against an oxidative 
insult (tBHP).  The data to date highlight the potential usefulness of antioxidant therapy in FSHD. 
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4. [P] 
 
DNA combing assay for detection of contraction-dependent facioscapulohumeral muscular 
dystrophy (FSHD1) 
 
F.Z. Boyar1, P. Chan1, V. Sulcova1, D. Tsao1, R. Owen1, P. Walrafen2, C.D. Braastad3, M. Jocson3, W. 
Sun1, A. Anguiano1, C.M. Strom1 
 
1 Department of Genetics, Quest Diagnostics Nichols Institute, San Juan Capistrano, California  
2 Diagnostics Division, Genomic Vision, Paris, France 
3 Athena Diagnostics Inc., Worcester, Massachusetts 
 
Abstract: FSHD, the third most common muscular dystrophy, is an autosomal dominant disorder with a 
prevalence of 4-10 per 100,000. It is characterized by often asymmetric progressive weakness of facial, 
scapular and upper arm muscles. FSHD1 is associated with contraction of the D4Z4 region (3.3 kb 
repeat motif that contains DUX4, double homeobox 4, gene) at the subtelomeric region of 4q35 and 
activation of the normally epigenetically silenced DUX4. Affected alleles have 1- 10 copies of D4Z4 on 
the 4qA allele, while unaffected alleles have 11-100 copies. Contractions of the partner 4qB allele or a 
homologous region on chromosome 10q26 are non–pathogenic. Previously, detection of truncated 
D4Z4 has been based on Southern blot (SB) analysis. SB analysis can only provide a size approximation, 
yields ambiguous results in at least 20% of cases and, as we show in this study, can miss affected 
mosaic individuals.  
 
DNA combing provides an attractive alternative method for the diagnosis of contracted alleles in FSHD.  
In this technology, individual DNA fibers are visualized and measured, allowing differentiation between 
A and B alleles and 4q and 10q alleles, accurate sizing of all alleles and identification of  mosaic affected 
individuals. We validated a laboratory developed test based on DNA Combing for the diagnosis of 
FSHD.  The validation series consisted of combed DNA from 2 cell lines and from leukocyte plugs from 
35 individuals submitted to Athena Diagnostics for SB. The samples were blinded to laboratory 
personnel performing the analysis. There was 100% concordance in the 7 samples determined to 
affected by SB analysis and the 2 cell lines. One of the 28 samples determined to be unaffected by SB 
analysis was demonstrated to be a mosaic individual with 2 normal sized alleles and a contracted 
affected allele. Our findings underscore the utility of a DNA combing assay for more accurate 
measurement of the D4Z1 locus on the pathogenic 4qA allele and diagnosis of FSHD1. This represents 
the first successful validation of a molecular combing assay in a United States commercial laboratory. 
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5. [P] 
 
Regulates Expression of the Pro-Apoptotic Gene, p63 
 
Jacqueline Domire, Lindsay Wallace, Susan Guckes, Jian Liu, Scott Q. Harper 
 
Center for Gene Therapy, The Research Institute at Nationwide Children’s Hospital, Columbus, Ohio, 
43205 USA 
 
Facioscapulohumeral muscular dystrophy (FSHD) is a dominant disorder that most commonly affects 
specific muscles of the face, shoulder girdle, and limbs.  There is no effective treatment for FSHD, and 
compared to other muscular dystrophies, translational research has been stagnant.  Understanding the 
molecular mechanisms underlying a disease is necessary for developing targeted therapeutic 
strategies.  For FSHD, translational research was impeded because the pathogenic events required for 
diseased development were elusive and/or controversial.  The landscape has changed recently with 
the emergence of DUX4 gene expression as an underlying pathogenic event in FSHD.  We can now 
begin developing rational therapies that directly target DUX4 as well as downstream pathways it 
controls, since the DUX4 transcription factor likely initiates a cascade of gene expression changes that 
are incompatible with normal muscle homeostasis.  
 
The objective of this study was to characterize prospective DUX4-controlled pathways.  We 
hypothesized that this approach would help further define the pathogenic events involved in FSHD and 
identify new therapeutic targets.  Toward this end, we used microarray data from DUX4-
overexpressing muscle to identify potential transcriptionally regulated targets of DUX4.  We found that 
several genes involved in apoptosis pathways were up-regulated, including p53-pathway members.  
The latter finding was consistent with our previous finding that DUX4-associated myopathy was p53-
dependent in mice.  Since DUX4 is a transcription factor, we therefore hypothesized that it could 
directly activate p53-pathway genes.  In this study, we focused on one such gene, p63, because it was 
increased in DUX4-expressing muscles and cells, known to transactivate p53 target genes, and sensitize 
cells to apoptosis.  We found that DUX4 binds to the p63 promoter to regulate its expression, and p63 
inhibition mitigates the pro-apoptotic activity of over-expressed DUX4.  We showed preliminary data 
supporting the DUX4-p63 relationship at last year’s FSH Society meeting, and will discuss additional 
data accumulated during the last year on this project, including p63 co-localization with DUX4 in vivo.  
Together, these results suggest that p63 may be a downstream target of DUX4, and may play an 
important role in DUX4-mediated cell death. As such, p63 could be a therapeutic target for FSHD, and 
we are currently investigating p63 expression, and that of other p53 pathway members, in biological 
material from human FSHD patients.  
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6. [P] 
 
Breaking the rule of autosomal dominant inheritance in Facioscapulohumeral muscular dystrophy 
 
Hulya Gundesli1, Ana Nikolic2, Rachele Piras3 , Stefania Murru3, Isabella Scionti2, Maurizio Moggio4, 
Giuliano Tomelleri5, Maria Antonietta Maioli3, Rossella Tupler1,2 
 
1 Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, 
Massachusetts 01605, USA 
2 Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy 
3 Neuromuscular Unit, Multiple Sclerosis Center, Department of Cardiovascular and Neurological 
Sciences, University of Cagliari, Cagliari, Italy 
4 Department of Neurology, IRCCSFondazione Ospedale Maggiore Policlinico, University of Milan, Milan 
20122, Italy 
5 Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University 
of Verona, 37134 Verona, Italy 
 
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common, progressive and 
genetically heterogeneous myopathy with estimated prevelance of 1 in 20,000 people. FSHD has been 
causally related to reduction of tandemly arrayed 3.3 kb repeat units (D4Z4) on chromosome 4q35. The 
number of D4Z4 repeats varies from 11 to 100 in the general population, whereas less than 11 repeats 
are present in sporadic and familial FSHD patients.  
 
FSHD is considered an autosomal dominat disorder. However, several cases, which escape this model, 
have been identified. Determining the mode of inheritance in FSHD families is important to understand 
how to analyze these patients and could play a critical role in identifying genetic defect/s which has not 
been discovered yet. For this reason in this study, we have analyzed 101 families both clinically and 
genetically. Among these, we have identified nine FSHD families suggestive of autosomal recessive 
inheritance. In one of these families, Family 1, there are two affected sisters present clinical features of 
severe FSHD. Neither parents nor other distant relatives display myopathic signs. Molecular analysis of 
the FSHD locus at 4q35 failed to detect alleles with a reduced number of D4Z4 repeats. Haplotype 
analysis of the family through three generations including parents and children by using genetic 
markers close to 4q35 region demonstrated that both affected sisters and unaffected brother share 
the same haplotype. No hypomethylation at the D4Z4 locus was found in two sisters in comparison 
with other family members. Interestingly, this family is from a small village in inner Sardinia and three 
sibs died at very young age of beta-thalassemia. Both parents are heterozygotes for the ß⌃039 
mutation in the beta globin gene. Collectively, these observations suggest that in this family FSHD is 
most likely caused by an autosomal recessive defect not associated with the 4q-FSHD locus. The other 
family, Family 2, has two affecteds with several unaffected relatives. Parents of the affecteds have no 
FSHD which supports the mode of inheritance as autosomal recessive. Molecular genetic analysis has 
demonstrated that there is no correlation between D4Z4 repeats, 4A161PAS haplotype and disease. In 
addition, we have identified another autosomal recessive inherited FSHD family (Family 3) with two 
affecteds in which parents of the two affected-siblings are all healthy. There is no correlation between 
D4Z4 repeat size and disease phenotype.  
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At present, no FSHD genetic locus other than 4q35 has been identified. Extended clinical and molecular 
analysis of FSHD families demonstrate that there are families in which FSHD is inherited as autosomal 
recessive disease. Studying these families will be invaluable to find novel genetic defect/s and will 
provide critical information to understand the pathogenesis of FSHD. 
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7. 
 
miRNA-411 negatively regulates YAF2 and myogenesis 
 
Naoe Harafuji1, Peter Schneiderat2 and Maggie C Walter3, Yi-Wen Chen1,4 
 
1 Center for Genetic Medicine Research, Children’s National Medical Center, Washington DC 
2 Department of Neurology, Ludwig-Maximilians-University of Munich, Germany 
3 Friedrich-Baur-Institute, Department of Neurology, Ludwig-Maximilians-University of Munich, 
Germany  
4 Department of Integrative Systems Biology and Department of Pediatrics, George Washington 
University, Washington DC 
 
Previous studies suggest that defects in myogenesis are involved in the disease mechanisms of 
facioscapulohumeral muscular dystrophy (FSHD). In this study, we hypothesized that misregulation of 
microRNAs (miRNAs) in FSHD is involved in the myogenic defects and disease progression. To identify 
misregulated miRNAs in FSHD myoblasts, miRNA expression profiling was performed using TaqMan 
microRNA arrays.  Eight miRNAs were differentially expressed in FSHD myoblasts during proliferating.  
The differential expression of miR-411 was validated by individual quantitative RT-PCR assay and 
additional arrays.  In situ hybridization showed cytoplasmic localization of miR-411 in the myoblasts.  
The mRNA expression changes of the myoblasts were determined by mRNA expression profiling, and 4 
potential miRNA-411 targets including YY1 associated factor 2 (YAF2) were identified.  Over-expression 
of miR-411 in murine myoblasts, C2C12 cells, showed a reduction of YAF2 mRNA expression and 
myogenic factors myoD and myogenin.  The findings suggest that the higher expression of miR-411 in 
FSHD primary myoblasts might be involved in the defects of myogenesis reported in FSHD.
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8. 
 
MR as biomarker for disease evaluation in facioscapulohumeral dystrophy 
 
Barbara H. Janssen¹, Rob J.W. Arts², Nicoline B.M. Voet³, Christine I.H.C. Nabuurs¹, Alexander Geurts³, 
George W. Padberg², Baziel G.M. van Engelen² and Arend Heerschap¹ 
 
¹ Department Radiology, Radboud University Nijmegen Medical Centre, the Netherlands 
² Department Neurology, Radboud University Nijmegen Medical Centre, the Netherlands 
³ Department Rehabilitation, Radboud University Nijmegen Medical Centre, the Netherlands 
 
Introduction: Facioscapulohumeral dystrophy (FSHD) is the third most common muscular dystrophy. 
The disease is typically characterized asymmetry of skeletal muscle involvement. FSHD is associated 
with contraction of D4Z4 microsatellite repeats on chromosome 4q35, leading to a stabilized distal 
DUX4 transcript.  
 
The aim of this study  was to exploit whether MR imaging and spectroscopy can serve as a non invasive 
biomarker to asses disease severity, enable therapy evaluation and study disease pathobiology.  
Methods: 30 genetically proven FSHD patients were examined on a Sienens Trio 3T system. The 
measurements were performed on the upper leg to study the thigh muscles. Fat infiltration was 
quantitatively determined with the method earlier described by Kan (2009) . The ratio of the high 
energy compounds (PCr, ATP and Pi) and the pH of the muscles were studied with 31-phosphourus 
MRS. The strength of the quadriceps and hamstrings muscles was assessed by a myometry setup. 
Results and discussion: 353 thigh muscles were investigated, of which 232 twice. Analysis of the fat 
infiltration fraction showed that muscles of FSHD patients are nearly binary dived over a high and a low 
fat fraction. The muscle with an intermediate fat infiltration (around 50%) showed the largest increase 
in fat fraction over time. This combined suggests that once disease onset is triggered in a muscle this 
inevitably rapidly leads to muscle dysfunction.  Fat fraction of the quadriceps and hamstring muscles 
correlate with the muscle strength. PCr/ATP showed a significant decrease with increasing fat fraction, 
possibly in an attempt to compensate for overload in development towards a FSHD condition, for 
instance by adapting to a more oxidative phonotype.  
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9. [P] 
 
Natural progression of fatty infiltration and beneficial effects of non-pharmaceutical interventions in 
FSHD detected by quantitative MRI 
 
Barbara Janssen¹, Nicoline Voet², Rob Arts¹, Christine Nabuurs¹, George Padberg³, Alexander Geurts², 
Baziel van Engelen³, and Arend Heerschap¹ 
 
¹ Department Radiology, Radboud University Nijmegen Medical Centre, the Netherlands 
² Department Neurology, Radboud University Nijmegen Medical Centre, the Netherlands 
³ Department Rehabilitation, Radboud University Nijmegen Medical Centre, the Netherlands 
 
Introduction: Facioscapulohumeral dystrophy (FSHD) is the third most common muscular-dystrophy 
and is typically characterized by asymmetry of skeletal muscle involvement. 
 
The aim of this study was to employ the muscular fat fraction as a biomarker to follow the natural 
progression of the disease and to assess the effects of two non-pharmaceutical interventions: cognitive 
behavioral therapy (CBT) and exercise training (AET).    
 
Materials and methods: Twenty-four genetically proven FSHD patients were included. Patients were 
randomly placed in the control group (n=8), CBT group (n=8) or AET group (n=6) and were examined on 
a Siemens Trio 3T system. Measurements were performed on the thigh muscles of the patients before 
and four months after usual care or intervention period. Fat fraction was quantitatively determined 
with a method earlier described. 
 
Results: The difference in fat fraction between before and after measurement was shown to be 
dependent on the initial fat fraction. In the controls relative most changes in fat fraction were 
observed in muscle having an initial intermediate fat fraction. This observed change was also largest in 
these muscles.  Unpaired two-tailed t-test revealed significantly smaller increases in fat fraction over 
time for the CBT and AET group. However no differences were observed between the intervention 
groups. 
 
Discussion and conclusions: The difference in fat fraction between before and after control or 
intervention period was shown to be dependent on the initial fat fraction. In controls the fat fraction 
increases significantly over time. Remarkably, the increase in fat fraction was more common and larger 
in the intermediary muscles compared to the normal muscle. 
 
Non pharmaceutical interventions like cognitive behavioral therapy or exercise training appears to be 
beneficial in FSHD as it was shown to slow down disease progression defined as increasing fatty 
infiltration.  
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10. [P] 
 
On nosological place of facioscapuloperoneal (or facioscapulolimb, type 2) 4q35-linked muscular 
dystrophy once again 
 
Valery Kazakov, Dmitry Rudenko, Vladislav Kolynin 
 
Department of Neurology, Pavlov State Medical University, St. Petersburg, Russia 
   
We observed the pattern of muscle weakness in 28 patients from fourteen 4q35-linked EcoRI/BlnI DNA 
fragment size 13-30 kb facioscapuloperoneal muscular dystrophy (FSPMD) families (Table).  The 13 
patients (8 men and 5 women) from these families were re-examined by V.K. after 27-29 years (4 
patients), after 36-37 years (n=5), after 43 years (n=1), after 48 years (n=1) and after 49 years (n=2) 
(Table). In the first examination  the next phenotypes of muscle weakness were found: facio(scapular) 
[F(S)] (1 patient), (facio)scapular [(F)S] (n=3), facioscapular (FS) (n=1), (facio)scapuloperoneal [(F)SP] 
(n=5), (facio)scapuloperoneal-(femoral) [(F)SP(F)] (n=1), scapuloperoneal (SP) (n=1),  and 
facioscapuloperoneal-(humeral) [FSP(H)] (n=1) (Table).  On re-examination (V.K.) these patients after 
27-49 years the next  muscle phenotypes were found:  facio-scapulo-peroneal-femoro (posterior thigh 
muscles)-gluteo (gluteus maximus) (FSPFG) (1 patient), FSPF(G) (n=1), (F)SPFG (n=1), facio-scapulo-
peroneal-femoro (posterior thigh muscles)-gluteo (gluteus maximus)- (humeral; biceps brachii) 
[FSPFG(H)]  (n=3), [(F)SPFG(H)]  (n=1), facio-scapulo-peroneal-humero (biceps brachii) - femoral 
(posterior thigh muscles)-gluteal (gluteus maximus) (FSPHFG) (n=1), (F)SPHFG (n=1),  
(facio)scapuloperoneal [(F)SP)] (n=2), facioscapuloperoneal (FSP) (n=1) and  facioscapuloperoneal-
(femoral) [FSP(F)] (n=1) (Table). Thus, in nine patients their phenotypes of muscle weakness were 
transferred in final ones: in FSPFG or FSPFG(H) in seven patients and in two other patients – in FSPHFG 
phenotypes in who the biceps brachii muscles were severe affected after involving of tibialis anterior 
muscles. Three patients (F2, III-10 and VI-8; F8, III-25) after 37, 36 and 27 years, respectively, had the 
same clinical pure FSP phenotype and in one patient (F8, VI-17) after 36 years the FSP phenotype  
predominated  as well but with slight involvement of posterior thigh muscles (Table). However, in all 
these patients (excluding F8, III-25) on MRI study the severe involvement of some posterior thigh 
muscles and rectus femoris was found. Thus, in discussed patients the disease began with initial 
involvement of the face (in minimal/slight degree) and shoulder girdle muscles and some time later of 
the peroneal group (anterior tibial) muscles. However, later the dystrophic process gradually was 
extended to the thigh muscles (posterior group, namely; the quadriceps were preserved), pelvic girdle 
muscles (gluteus maximus, namely; the gluteus medius were preserved) and not always on upper arm 
muscles (biceps brachii, namely; slightly weakened on the one side in four of 13 patients only; in two 
other patients these muscles were severe affected). In patients having the final phenotype the 
abdominal muscles were involved after affection of the peroneal group muscles and the increased 
lumbar lordosis was due to weakness of abdominal and gluteus maximus muscles but not the erector 
trunci ones. All patients having the final phenotype of muscle weakness could walk independently and 
climb the stairs with the aid of a railing excluding two patients (F13, III-8 and F8, II-13) who could walk 
with aid of a stick on short distances only.  
 
In other 10 symptomatic patients who were re-examined (V.K.) after 3-24 years the similar final FSPFG 
(n=2), (F)SPFG (n=1) FSPFG(H) (n=1), FSPHFG (n=3), FSPHF(G) (n=1), (F)SP(FGH) (n=1) and FSP(F) (n=1) 
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phenotypes were found and only 1 patient had pure FSP phenotype after  re-examination over 7 years 
(Table). 
 
The term “facioscapulolimb muscular dystrophy, type 2 (FSLD2), descending with a “jump” with initial 
FSP phenotype (Erb, Landouzy and Dejerine type)” would be more correct. The FSP or (F)SP phenotype 
constitutes merely a stage in the development of FSLD2. We suppose that classical AD FSPMD (or 
FSLD2, a descending with a “jump” type with initial FSP phenotype) is different from the classical AD 
FSHD which was called as a facioscapulolimb muscular dystrophy, type 1 (FSLD1), a gradually 
descending with initial FSH phenotype (Duchenne de Boulogne type) and may be these diseases are 
connected with the various 4q35 chromosomal mutations (1-3). 
 
Table 
 
Dynamic of myogenic phenotypes and degree of severity disease in 28 patients from 14 families with 
different EcoRI/BlnI DFS   
 
 
№F 
 
 
DFS 
Кb 
 
№P 
in 
ped. 
 
Age 
ex. 
 
      Ph1 
 
D.S.1 
D 
L 
W 
D1 
 
 
 
Re 
ex. 
yrs 
 
Age 
reex
. 
 
      Ph2 
 
D.S.2 
D 
L 
W 
D2 
1 26/23 IV-42  31 (F)SP Pr 1  24  55 (F)SP(FGH) Modd 3 
2 27/24 III-7 36h (F)SP Modd 2  37  73 FSPFG(H) Sdd 3 
  III-10 36 (F)SP Sdd 2  37  73 (F)SP Sdd 2 
VI-8 6 (F)S Pr 1  36  42 FSP Modd 2 
 
5 
 
25/22 
 
IV-7 
 
23 
 
(F)SP(F) 
 
Sdd 
 
2 
 
 29 
 
 52 
 
FSPF(G) 
 
Sdd 
 
3 
  V-4 1,5 Norma   22.
5 
 24 (F)S(P) Pr 1 
 
8 
 
23/20 
 
II-13 
 
60 
 
(F)SP 
 
Sdd 
 
2 
 
 28 
 
 88 
 
(F)SPFG(H) 
 
Sdd 
 
4 
  III-25 28 (F)SP Pr 1  27  55 (F)SP Mdd 1 
VI-17 5.5 F(S) Pr 1  36  41 FSP(F) Sdd 2 
 
18 
 
27/24 
 
III-3 
 
18h 
 
(F)S 
 
Mdd 
 
1 
 
 49 
 
 67 
 
FSPFG(H) 
 
Sdd 
 
3 
 
20 
 
16/13 
 
III-2 
 
73 
 
FSP(FG) 
 
Sdd 
 
2 
 
  7 
 
 80 
 
FSPFG(H) 
 
Sdd 
 
3 
  III-10 62 FSPH(FG) Sdd 2   3  65 FSPHF(G) Sdd 3 
IV-2 18h FS Mdd 1  43  61 FSPFG(H) Sdd 3 
 
19 
 
20/17 
 
III-4 
 
47h 
 
(F)S 
 
Mdd 
 
1 
 
  8 
 
 55 
 
(F)SPFG 
 
Sdd 
 
2/
3 
  IV-2 19h FSP Mdd 1  13  32 FSPHFG Sdd 3/
4 
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16 23/20 III-5 45 FSP Sdd 2  13  58 FSPFG Sdd 3 
  IV-9 21 FSP Modd 2  15  36 FSP(F) Modd 2/
3 
IV-10 17 FSPH(FG) Sdd 2  18  35 FSPHFG Sdd 3/
4 
 
21 
 
17/14 
 
II-6 
 
49 
 
FSP 
 
Mdd 
 
1 
 
 11 
 
 60 
 
FSPFG 
 
Modd 
 
3 
 
 
 
 
Ш-5 
III-6 
25 
14 
FSPHFG 
(F)S(P) 
Sdd 
Pr 
3 
1 
 14 
 12 
 39 
 26 
FSPHFG  
(F)S(P) 
Sdd 
Pr 
4 
1 
 
22 
 
23/20 
 
III-1 
 
42 
 
FSP 
 
Modd 
 
2 
 
  7 
 
 49 
 
FSP 
 
Sdd 
 
2 
 
13а 
 
26/23 
 
III-1 
 
18h 
 
(F)SP 
 
Pr 
 
1 
 
 27 
 
 45 
 
FSPFG 
 
Sdd 
 
2 
 
9а 
 
16/13 
 
IV-1 
 
25h 
 
(F)S 
 
Pr 
 
1 
 
 49 
 
 74 
 
(F)SPFG 
 
Sdd 
 
3 
 
13 
 
 
28/25 
 
III-8 
 
26h 
 
FSP(H) 
  
Sdd 
 
2 
 
 37 
 
 63 
 
FSPHFG 
 
Sdd 
 
4 
15 
 
 
 
 
24/21 
33/30  
 
IV-3 
V-10 
V-17 
 
20h 
10 
15 
 
 SP 
 S 
(F)S 
 
Pr 
Pr 
Pr 
 
1 
1 
1 
 
 48 
 24 
 24 
  68 
  34 
  39 
(F)SPHFG 
(F)S(P) 
(F)S(P) 
Sdd 
Pr 
Pr 
3/
4 
1 
1 
 
List of the abbreviations used in the Table 
 
№F = number of family; DFS kb = EcoRI/BlnI DNA fragment size (kilobas); №P in ped. = number of 
patient in pedigree; Age ex. = age of patient in first examination; 18h, 47h and other = age of patients 
in who the myogenic pattern  was take from the case history; Ph1 = patient’s phenotype in first 
examination; D.S.1  = the degree severity of disease in first examination: Pr – presymptomatic,  Mdd – 
mild degree of disease,  Modd – moderate degree of disease, Sdd- severe degree of disease (see Acta 
Myol. 2000; vol. XIX, p.71); DLWD1 = daily-life  work disability in first examination (see Acta Myol. 
2000; vol. XIX, p. 72);  Age reex. = the patient’s age in which he was re-examined; Reex. yrs = after what 
years the patient was re-examined by Dr. V. Kazakov.; Ph2  = patient’s phenotype after re-examination; 
D.S.2 = the degree severity of disease after re-examination; DLWD2 = daily-life work disability after re-
examination.  
 
 Phenotypes: FS = facioscapular; S = scapular; SP =scapuloperoneal; FSP = facioscapuloperoneal; 
FSPFGH = facio-scapulo-peroneal-femoro (posterior group muscles)-gluteo (gluteus maximus muscle)-
humeral (biceps brachii muscle); FSPFG = facio-scapulo-peroneal-femoro (posterior group muscles)-
gluteal (gluteus maximus muscle); FSPHFG = facio-scapulo-peroneal-humero (biceps brachii muscle)-
femoro (posterior group muscles)-gluteal (gluteus maximus muscle). 
(F) = slight atrophy and weakness of upper or lower half of orbicularis oris muscle and slight weakness 
of orbicularis oculi muscles (orbital part); (S) = slight atrophy lower part of trapezius muscles; (H) = 
slight weakness (grade 4) of biceps brachii muscle; (F) = slight weakness of posterior thigh muscles; 
(FG) = slight weakness of posterior thigh and gluteus maximus muscles; (FGH) = slight weakness of 
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posterior thigh, gluteus maximus and some facial muscles; (P) = slight weakness of tibialis anterior 
muscles (the patient cannot stand up on his heels/or on one hell). The patient’s phenotypes who were 
re-examined over 27-49 years marked by rich black color.  
 
Kazakov V. M., Bogorodinsky D.K., Znoyko Z.V., Skorometz A.A. The facio-scapulo-limb (or the 
facioscapulohumeral) type of muscular dystrophy. Clinical and genetic study of 200 cases. Eur. Neurol. 
1974; 11: 236-260. 
 
Kazakov V. History of the recognition and description of the facioscapulohumeral muscular dystrophy 
and on the priorities of Duchenne, Erb, Landouzy and Dejerine. Acta Cardiomiol. 1995; VII: 79-84. 
 
V. Kazakov, D. Rudenko, A. Skorometz. Facioscapulohumeral Muscular Dystrophy and it connected with 
the Facioscapuloperoneal Muscular Dystrophy Linked with Chromosome 4q35: History, Clinical, 
Genetics and Differential Diagnosis.  Polytechnika edn, St. Petersburg, 2008: 374 pp. 
 
E-mail: valerykazakov@mail.ru , Tel. +7 812 510 93 81, fax: +7 812 513 26 12 
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11. 
 
Sarcomeric dysfunction in facioscapulohumeral muscular dystrophy 
 
Saskia Lassche MD¹, Ger JM Stienen PhD², Tom C Irving PhD³, Silvere M van der Maarel PhD⁴, George W 
Padberg MD, PhD¹, Baziel GM van Engelen MD, PhD¹, Coen  AC Ottenheijm PhD² 
 
¹ Department Neurology, Radboud University Medical Center Nijmegen, The Netherlands 
² Department Physiology, VU University Medical Center, Amsterdam, The Netherlands 
³ Department Biological Chemical Sciences, Illinois Institute of Technology, Chicago, Illinois 
⁴ Department Human and Clinical genetics Leiden University, Medical Center, Leiden, The Netherlands 
 
The expression of sarcomeric proteins is impaired in facioscapulohumeral muscular dystrophy (FSHD), 
a common hereditary myopathy characterized by muscle weakness. In addition, overexpression of 
DUX4, the leading FSHD candidate gene, has been shown to activate pathways involved in sarcomeric 
protein degradation. Here we investigated whether sarcomeric dysfunction contributes to muscle 
weakness, using demembranated single muscle fibers of FSHD patients and control subjects. The force 
generating capacity of sarcomeres is significantly impaired in FSHD. Sarcomeric weakness was 
restricted to type II muscle fibers, in which maximum force generation was only 70% of normal 
strength. In contrast to active force measurements, a 5- to 12-fold increase in passive force was seen in 
type I and type II fibers respectively, indicating stiffening of titin molecules. Corroborating these 
findings, we observed a decrease in myofilament lattice spacing and increase in calcium sensitivity, 
both physiological consequences of titin stiffening.  
 
Based on these findings, we propose that sarcomeric dysfunction plays a critical role in muscle 
weakness in FSHD.  
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12. 
 
Identification of the epigenetic modifier of the D4Z4 epiallele in FSHD2 
 
Richard J.L.F. Lemmers1,*, Rabi Tawil2,*, Lisa M. Petek3, Judit Balog1, Gregory J. Block3, Gijs W.E. 
Santen4, Amanda M. Amell3, Patrick J. van der Vliet1, Rowida Almomani4, Kirsten R. Straasheijm1, 
Yvonne D. Krom1, Rinse Klooster1, Yu Sun1, Johan T. den Dunnen1,4, Quinta Helmer5, Colleen M. Donlin-
Smith2, George W. Padberg6, Baziel G.M. van Engelen6, Jessica C. de Greef1,$, Annemieke M. Aartsma-
Rus1, Rune R. Frants1, Marianne de Visser7, Claude Desnuelle8, Sabrina Sacconi8, Galina N. Filippova9, 
Bert Bakker4, Michael J. Bamshad3, Stephen J. Tapscott9,#, Daniel G. Miller3,#, Silvère M. van der 
Maarel1,# 
 
1 Department of Human Genetics, Leiden University Medical Center, Leiden, Netherlands 
2 Neuromuscular Disease Unit, Department of Neurology, University of Rochester Medical Center, 
Rochester, New York, USA 
3 Department of Pediatrics, University of Washington, Seattle, Washington, USA. Seattle Children’s 
Hospital, Seattle, Washington, USA 
4 Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands 
5 Department of Medical Statistics and Bioinformatics, Leiden University Medical Center, Leiden, 
Netherlands 
6 Neuromuscular Centre Nijmegen, Department of Neurology, Radboud University Nijmegen Medical 
Centre, Nijmegen, Netherlands 
7 Department of Neurology, Academic Medical Center, Amsterdam, Netherlands 
8 Centre de référence des Maladies neuromusculaires and CNRS UMR6543, Nice University Hospital, 
Nice, France 
9 Division of Human Biology, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA 
 
Facioscapulohumeral muscular dystrophy (FSHD) is a common form of muscular dystrophy in adults. 
FSHD is associated with chromatin decondensation of the D4Z4 macrosatellite array on chromosome 4 
and ectopic expression of the D4Z4-encoded germ line transcription factor DUX4 gene in skeletal 
muscle. Two equally common variants of D4Z4 have been identified of which only one is permissive to 
DUX4 expression. In most patients, DUX4 derepression is caused by contraction of the D4Z4 array 
(FSHD1) and is inherited as a dominant trait. However, in some patients the D4Z4 decondensation 
occurs on normal sized arrays (FSHD2) of both chromosomes 4q and 10q and show a more complex 
inheritance pattern. In both FSHD1 and FSHD2, the chromatin relaxation is associated with a loss of 
CpG methylation and a loss of repressive histone modifications at D4Z4. Here we show that rare, 
normally benign variants in a chromatin modifier segregate with genome-wide D4Z4 CpG 
hypomethylation. FSHD2 patients inherited both variants of this epigenetic modifier and normal-sized 
D4Z4 arrays permissive for DUX4 expression. In conclusion, we identified an epigenetic modifier of the 
D4Z4 epiallele that is underlying FSHD2 and possibly other human diseases subject to epigenetic 
regulation. 
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13. 
 
Use of a simple Clinical Proforma to identify potential cases of FSHD2 in DNA diagnostic service 
testing for FSHD1 
 
Peter Lunt1, Rebecca Whittington2, Suzanne O’Shea2, Jenny Corfield2 and Maggie Williams2 
 
1 Clinical Genetics, St Michael's Hospital, Southwell Street, Bristol, BS2 8EG, United Kingdom 
     (peter.lunt@geneticseducation.nhs.uk) 
2 Bristol Genetics Laboratory, Pathology Sciences, Southmead Hospital, Southmead Road, Bristol,  
   BS10   5NB, United Kingdom 
 
The Bristol Genetics Laboratory (BGL) receives over 300 requests for FSHD testing (diagnostic, 
predictive and prenatal ) each year, providing the majority of tests for the UK, and some service 
provided for Europe and other continents.  Most requests (~80%) are for primary diagnostic testing of 
index cases affected with neuromuscular symptoms using EcoR1/Bln1/Apo1 triple digests where a 
shortened ≤35kb 4q band is detected with the p13E11 probe in 38% of referred cases.  
Further testing is by re-request from the referring clinician, who is required to complete a standard 
simple Clinical Proforma, which undergoes clinical/laboratory review. These are returned to us for 
around 30% of the initial negative diagnostic test results (approx 40 proforma returned /year).   
Exclusion criteria for FSHD such as ptosis, extraocular weakness, marked excess of pelvic over shoulder 
girdle weakness, or very high serum CK (>1500 IU/l) will result in alternative advice to the referring 
clinician.  However, in clinically compatible cases, including where there is a marked discrepancy 
between a severe clinical presentation and a borderline-sized residual fragment we recommend reflex 
testing for proximal deletions using MseI/EcoRI/BlnI digests and the D4Z4 1kb probe finding only 1-3 
extended deletion cases per year (estimated ~ 1% of total requests).   
 
Annually approximately 30 test-negative samples remain (10% of total requests) where the proforma 
suggests that a clinical diagnosis of FSHD remains very plausible. It is amongst this group that we 
anticipate that a test for FSHD2 will become highly valuable, as well as using a targeted next generation 
sequencing approach to identify conditions such as calpainopathy and acid maltase (alpha glucosidase) 
deficiency in the differential diagnosis of FSHD2.   
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Understanding mRNA Processing 
 
Antoine de Morrée and Thomas A Rando 
 
VAPAHCS, 3801 Miranda Avenue, Palo Alto, CA 94304 USA 
The Glenn Laboratories for the Biology of Aging  
Department of Neurology and Neurological Sciences, School of Medicine, Stanford University 
Stanford Neurology Clinic, 300 Pasteur Drive, Boswell A-301, Stanford, CA 94305 USA 
 
FSHD develops in individuals who have BOTH a D4Z4 repeat contraction, causing chromatin relaxation, 
AND a PolyAdenylation Site (PAS) in the pLAM domain distal to the D4Z4 array. This PAS allows for 
cleavage of the pre-mRNA and subsequent polyadenylation and stabilization of the transcript. In 
individuals who have D4Z4 contractions but a single base change in the PAS, the cell does not recognize 
it as a PAS, preventing cleavage and polyadenylation. As a result the DUX4 transcript is unstable, no 
DUX4 protein is made, and the individuals are protected from getting the disease. Therefore, any 
intervention that prevents the addition of the poly(A) tail to the DUX4 transcript is a potential 
therapeutic approach for FSHD. Clearly, it is untenable to interfere with mRNA processing in general 
because of the toxicity to the cell. Therefore, understanding the mechanisms by which a cell can 
bypass a specific PAS would suggest a mechanism for selectively blocking the PAS in the DUX4 gene 
without generally affecting cellular mRNA processing. This would be an effective treatment for patients 
with FSHD. We hypothesize that sequence elements around the PAS unique to the that gene define the 
site of mRNA cleavage and polyadenylation and that specific sequences instruct a cell to select or 
bypass the PAS. The PAX3 gene has three functional PASs in its 3’UTR and encodes a transcript that is 
alternatively polyadenylated in different populations of quiescent muscle stem cells. Here we describe 
the characterization of the PAX3 3’UTR and discuss its implications for mRNA processing in general, 
and we discuss an assay to measure mRNA 3’UTR length. 
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Autophagy defects in FSHD 
 
Sachchida Nand Pandey1, Naoe Harafuji1, Rongye Shi1, Sara Winokur2, Charles Emerson3, Yi-Wen 
Chen1,4 
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3 NIH NICHD Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Center, and Boston 
Biomedical Research Institute, Watertown, Massachusetts 
4 Department of Integrative Systems Biology and Department of Pediatrics, George Washington 
University, Washington DC 
 
Using mRNA profiling and immunoblotting, we detected autophagy defects in a tet-repressible muscle-
specific Pitx1 transgenic mouse model, including up-regulation of a master autophagy regulator, Dram, 
up-regulation of p62 and accumulation of ubiquitinated proteins.  The up-regulation of DRAM was also 
observed in FSHD muscle biopsies but not DMD or controls. We further characterized the autophagy 
state in immortalized FSHD myoblasts by immunoblotting.  Similar to the mouse model, higher 
expression of DRAM, p62 and ubiquitinated proteins were detected in immortalized FSHD myoblasts. 
In addition, lower LC3B-II/LC3B-I ratio were observed suggesting suppression of autophagy in the FSHD 
myoblasts. While the activation of DRAM is expected to activate the downstream autophagy pathways, 
the autophagy process is somehow disrupted in immortal FSHD myoblasts. The findings suggest 
involvement of autophagy defects in FSHD.
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FSHD is a progressive neuromuscular disorder caused by contractions of repetitive elements within the 
macrosatellite D4Z4 on chromosome 4q35. The pathophysiology of FSHD is unknown and as a result, 
there is currently no effective treatment available for this disease. In order to better understand the 
pathophysiology of FSHD and develop mRNA-based biomarkers of affected muscles, we compared 
global analysis of gene expression in two distinct muscles obtained from a large number of FSHD 
subjects and their unaffected first-degree relatives. Gene expression in two muscle types was analyzed 
using GeneChip Gene 1.0 ST arrays: biceps, which typically shows an early and severe disease 
involvement, and deltoid, which is relatively uninvolved.  For both muscle types, the expression 
differences were mild: using relaxed cutoffs for differential expression (fold-change ≥1.2 and nominal 
P-value <0.01), we identified 191 and 110 genes differentially expressed between affected and control 
samples of biceps and deltoid muscle tissues, respectively, with 29 genes in common. Controlling for a 
false-discovery rate <0.25 reduced the number of differentially expressed genes in biceps to 188 and in 
deltoid to 7. Expression levels of 15 genes altered in this study were used as a “molecular signature” in 
a validation study of an additional 26 subjects, and predicted them as FSHD or control with 90% 
accuracy based on biceps and 80% accuracy based on deltoids.  
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Facioscapulohumeral muscular dystrophy (FSHD) is classified as an autosomal dominant myopathy 
associated with deletions of integral copies of tandem 3.3 kilobase repeats (D4Z4) combined with 
4A(159/161/168) PAS haplotype at 4q35. It has been estimated an almost full penetrance of the 
disease by the age of 20. However, studies reported a unexpected high percentage of asymptomatic or 
minimally affected subjects carrying a reduced D4Z4 allele (DRA) at 4q. Recently we have reported that 
3% of healthy subjects carried alleles with reduced number (4-8) of D4Z4 repeats on chromosome 4q.  
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Through the Italian National Registry, 530 subjects carrying DRA (367 relatives and 167 probands) from 
176 unrelated FSHD families were clinically and molecularly evaluated. Size of DRA, gender, age, 
degree of kinship and 4q haplotype were evaluated to establish the role of these variable on severity of 
the clinical expression. The FSHD scale was used to define muscle impairment, which can be translated 
into a number (FSHD score).  
 
Overall, 32•2% of relatives did not display any muscle functional impairment, with 47•1% of 
unaffected individuals among second- through third-degree relatives and 27•5% among first-degree 
family members. The estimated risk of developing FSHD for relatives carrying DRA with 1-3 repeats was 
64•3% at age 20, 80•1 at age 40, and 96•2 at age 60. The risk of FSHD for relatives carrying DRA with 
4-8 repeats was approximately 20% at age 20, 43% at age 40, 65% at age 60.  
 
Comparison of the FSHD score given to females versus males with DRA of the same size , displays that 
male relatives received a mean score significantly higher than females relatives (mean FSHD score: 5.4 
in males vs 4.0 in females, p0.003). No 4q haplotype was exclusively associated with the presence of 
disease.  
 
Our work establishes that DRAs with 4-8 repeats have limited prognostic value. In this class of alleles 
female gender and degree of kinship are associated with a reduced risk of developing FSHD. No specific 
haplotype is predictive of disease expression. 
 
Collectively our data suggest that the pathogenesis of FSHD is more complex than previously thought 
and that the current genetic molecular signature needs to be carefully re-considered as predictor of 
disease outcome, with crucial consequences for genetic counseling and prenatal diagnosis. 
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FSHD, a fœtal pathology ? 
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Introduction: FSHD is a dystrophic pathology mainly of the adolescent or the young adult. The disease 
is suspected to be associated to a modulation of the expression of different genes located in the 4q35 
chromosomal region. Our objective was to characterize the presence of pathological signs during the 
fetal life and define the expression pattern of the 4q35 genes. 
 
Methods: Muscular biopsies from fetuses were obtained from medical interruption of pregnancy. The 
biobank is constituted with biopsies from fetuses carrying a deletion of D4Z4 from parents affected 
with FSHD. The non-carrier controls are not affected by any identified genetic mutation or muscular 
pathology. RNA was extracted from biopsies, reverse transcribed and amplified by quantitative PCR 
using a Roche 480 lightcycler. GUSB were used as the reference gene. Expression analysis and 
Wilcoxon-Mann-Whitney test were performed by Gnumeric spreadsheet software version 1.10.16. 
 
Results: Three groups of gene have been quantified: (i) genes located on the 4q35.1 and 4q35.2 region, 
(ii) genes related to muscular physiology and (iii) genes involved in metabolism and signal transduction. 
Expression was measured for the 3 trimesters of pregnancy in biceps, quadriceps, diaphragm, brain 
and kidney. In FSHD biopsies, we observed an over-expression of different genes located at the 4q35 
region, including ANT1. Furthermore, we observed that the muscular physiology was impacted in 
fetuses carrying a shortened D4Z4 array. We did not observe an induction of MMP9 or a modulation of 
PABPN1, usually associated to dystrophic phenotype. We also observed that calcium related genes 
were over-expressed. PITX1 expression was down-regulated only in brain and kidney but not in biceps 
and quadriceps.  
 
Conclusion: We confirmed a modulation of some genes from 4q35 region in FSHD biopsies. This 
modulation was accompanied with signs of a muscular hypertrophic phenotype without signs of 
dystrophic process. In addition, over-expression of calcium channel genes was shown. Our results 
indicate that at the molecular level, a latent dystrophic disease is present in FSHD fetuses. 
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In recent years, the advances of knowledge in clinical, genetic and epigenetic features of 
facioscapulohumeral muscular dystrophy (FSHD) allowed the identification of two forms of FSHD, the 
classical autosomal dominant FSHD type 1, and FSHD type 2 characterized by identical clinical 
phenotype but associated with a different (epi)genetic defect.  
 
FSHD1 patients carry a contracted D4Z4 allele ≤ 11 repeats on a permissive 4QA chromosome, while 
FSHD2 patients display normal-sized D4Z4 alleles on chromosomes 4, marked hypomethylation of D4Z4 
loci on both chromosomes 4 and 10 and at least one permissive 4QA allele. Myotube cultures of FSHD2 
patients also express DUX4 in a variegated pattern of few myonuclei expressing abundant amounts of 
DUX4 protein. 
 
In the present study we analyzed a cohort of 42 unrelated FSHD1 patients (24 women, 18 men, mean 
age 58, [IQR 49-67]) followed in Nice neuromuscular disease center in order to establish a 
genotype/phenotype correlation between the number of repeated units and the severity of clinical 
phenotype evaluated by Manual Muscle Testing and Brooke and Vignos scale. A good 
genotype/phenotype correlation was established for all but four FSHD1 patients. These patients 
display a very severe clinical phenotype (3 out of 4 were wheelchair bound) in association with 9 or 10 
repeat units. The complete genotype of chromosome 4 and 10 D4Z4 loci and the methylation studies 
confirmed the presence of a contracted 4QA allele in all these patients consistent with FSHD1 
diagnosis, but also uncovered marked hypomethylation of both chromosomes 4 and 10, consistent 
with a FSHD2 diagnosis.  
 
We therefore studied the segregation of the contracted 4QA allele and of the hypomethylation of 
chromosomes 4 and 10 in two of these patient’s families.  This revealed that FSHD1 and FSHD2 have 
different genetic basis since the two diseases segregate independently. Subsequent genetic analysis 
identified mutations in the recently identified FSHD2 gene segregating with the disease in three of our 
families.  
 
Collectively, our study shows that FSHD1 and FSHD2 share a common pathophysiological pathway 
since they present an identical clinical phenotype and FSHD2 genetic defect, and that the FSHD2 gene 
may act as a modifier for disease in FSHD1 families. 
32 
FSH Society, Inc. FSHD International Research Consortium & Research Planning Meeting.  November 6, 2012 ©FSH Society 2012 
 
20. [P] 
 
Large scale population analysis challenges the current criteria for the molecular diagnosis of 
fascioscapulohumeral muscular dystrophy (FSHD) 
 
Isabella Scionti,1 Francesca Greco,1 Giulia Ricci,2 Monica Govi,1 Patricia Arashiro,3 Liliana Vercelli,4 
Angela Berardinelli,5 Corrado Angelini,6 Giovanni Antonini,7 Michelangelo Cao,6 Antonio Di Muzio,8 
Maurizio Moggio,9 Lucia Morandi,10 Enzo Ricci,11 Carmelo Rodolico,12 Lucia Ruggiero,13 Lucio Santoro,13 
Gabriele Siciliano,2 Giuliano Tomelleri,14 Carlo Pietro Trevisan,15 Giuliana Galluzzi,16 Woodring Wright,17 
Mayana Zatz,18  and Rossella Tupler1,19 
 
1 Department of Biomedical Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy 
2 Department of Neuroscience, Neurological Clinic, University of Pisa, Pisa 56126, Italy 
3 Program in Genomics, Division of Genetics, Informatics Program, Children’s Hospital, Harvard Medical 
School, Boston, Massachusetts 02115, USA 
4 Department of Neuroscience, Center for Neuromuscular Diseases, University of Turin, Turin 10126, 
Italy 
5 Unit of Child Neurology and Psychiatry, IRCCS “C.Modino” Pavia 27100, Italy 
6 Department of Neurosciences, University of Padua, Padua 35129, Italy 
7 Department of Neurology, S. Andrea Hospital, University of Rome "Sapienza", Rome 00189, Italy 
8  Center for Neuromuscular Disease, University "G. d'Annunzio", Chieti 66013, Italy 
9 Department of Neurology, IRCCS Fondazione Ospedale Maggiore Policlinico, University of Milan, 
Milan 20122, Italy 
10 IRCCS Foundation, C. Besta Neurological Institute, Milano 20133, Italy 
11 Department of Neurosciences, Università Cattolica Policlinico A. Gemelli, Rome 00168, Italy 
12 Department of Neurosciences, Psychiatry and Anaesthesiology, University of Messina, Messina 
98125, Italy 
13 Department of Neurological Sciences, University ‘‘Federico II,’’ Naples 80131, Italy 
14 Department of Neurological Sciences and Vision, University of Verona, Verona 37134, Italy 
15 Department of Neurological and Psychiatric Sciences, University of Padua, Padua 35100, Italy 
16 Molecular Genetics Laboratory of UILDM, Lazio Section, IRCCS Santa Lucia Foundation, Rome 00179, 
Italy 
17 Department of Cell Biology, UT Southwestern Medical Center, Dallas, Texas 75390, USA 
18  Human Genome Research Center, Depart. of Genetics and Evolutionary Biology, Institute of 
Biosciences, University of São Paulo, São Paulo 05508-090, Brazil 
19 Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester, 
Massachusetts 01605, USA 
 
The practice of medical genetics requires a clear, definite evaluation of the significance of 
mutations/variations of DNA sequences for diagnosis to provide prognostic information and genetic 
counseling. This is particularly important for a progressive disease with unpredictable onset and a high 
variability of clinical expression such as FSHD. Establishing the value of mutational events underlying 
genetic diseases may be complex even when there are simple patterns of inheritance in diseases with a 
well-characterized pathologic course. 
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FSHD seems to fall in this complex pattern even though it is currently considered a fully penetrant 
disease with a wide variability in clinical spectrum, ranging from subjects with very mild muscle 
weakness to wheelchair bound patients. However the wide use of this test revealed several exceptions 
to the original model. Through the years the threshold size of D4Z4 alleles has been increased from the 
original 28 kb (6 repeats) to 35 kb (8 repeats), with FSHD cases carrying D4Z4 alleles of 38-41 kb (9-11 
repeats) considered borderline alleles.  Additional genotype-phenotype studies led to the identification 
of subjects carrying D4Z4 reduced alleles with no sign of muscle weakness in FSHD families as well as in 
normal controls. The present results from our systematic clinical and molecular analysis of FSHD 
patients from the Italian National Registry for FSHD as well as a large number of healthy controls 
challenge the current model for FSHD diagnosis.  
 
Remarkably, our data establish as a general rule rather than an exception that detection of a D4Z4 
reduced allele is not sufficient to diagnose FSHD.  Although the majority of FSHD patients (70%) carry 
D4Z4 alleles with 4-8 units, this size range is carried by 3% of healthy subjects from the general 
population.  Additionally there is little predictive value of the 4qA161PAS haplotype in the absence of 
family history since 1.3% of healthy subjects carry this haplotype, which therefore has the frequency of 
a common polymorphism (Figure 1) rather than a rare mutation.  Finally 49 of 253 probands (19%) do 
not carry D4Z4 alleles with 1-8 repeats and only 50% of the probands carry the 4A161 permissive 
haplotype.  
 
In summary, our study indicates that a profound re-thinking of the genetic disease mechanism and 
modes of inheritance of FSHD are now required and entirely new models and approaches are needed. 
It is hoped that broadening the scope of investigations including next generation deep sequencing in 
particular in families with asymptomatic and clinically affected members carrying the same FSHD allele 
may finally lead to an understanding of the molecular pathogenesis of this complex disease. These 
findings have important clinical implications for genetic counseling of patients and families with FSHD 
with particular regard to the interpretation of data in prenatal diagnosis. 
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Primary CD56+ FSHD myoblasts fuse into myotubes presenting various proportions of an atrophic or a 
disorganized phenotype.   To better define those phenotypes, we optimized a differential isotope 
protein labeling (ICPL) combined with 2DLC-MS/MS to study their proteome as compared to healthy 
control myotubes. FSHD atrophic myotubes presented decreased relative abundance of structural and 
contractile muscle components. This phenotype suggests atrophy-associated proteolysis that likely 
results from the DUX4-mediated dysregulation cascade. The skeletal muscle myosin isoforms and non-
muscle myosin complexes presented a lower or higher relative abundance, respectively, that likely 
reflects a differentiation defect. In FSHD disorganized myotubes, myosin isoforms were unchanged, 
while proteins with increased relative abundance were mostly involved in microtubule network 
organization and myofibrillar remodeling.  
 
Because the predominantly atrophic or disorganized FSHD cultures that we have analyzed are derived 
from comparable patients in terms of the number of D4Z4 units, sex and age, we assume that other 
factors could intervene to explain the emergence of a non-atrophic phenotype, despite the expression 
of DUX4. The open chromatin at the D4Z4 repeat array in FSHD facilitates transcription of several 
genes in the vicinity, among which DUX4 within the D4Z4 unit itself and DUX4c located 42 kb 
centromeric. The DUX4c protein, expressed in myoblasts from healthy control individual and induced 
in FSHD, could bind to DUX4-target promoters through its identical double homeodomain but has a 
shorter carboxyl terminal domain and does not share DUX4 toxicity.  However, its overexpression in 
myoblasts led to an increased proliferation rate.  We have now evaluated the impact of DUX4c 
overexpression on myotube phenotypes. Control myoblasts overexpressing DUX4c fuse to form 
disorganized myotubes with clusters of nuclei, associated with the induction of β-catenin and an 
abnormal troponin T distribution and sarcomere structure. We developed siRNAs targeting the DUX4c 
mRNA. The addition of these inhibitors to primary disorganized FSHD myoblasts cultures suppressed 
DUX4c expression and restored a normal myotube phenotype.  
 
In conclusion, these results suggest that besides DUX4, DUX4c could be an additional target for the 
development of a therapeutic approach against FSHD.  
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The DUX4 promoter is expressed in FSHD-affected tissues  
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FSHD is most commonly characterized by progressive wasting and weakness of facial and shoulder-
girdle muscles, although no consistent pattern of penetrance or severity exists, even within affected 
families.  A hallmark characteristic of FSHD is asymmetrical muscle weakness.  There are also non-
muscular features including retinal vasculopathy and high frequency hearing loss.  Several recent 
breakthroughs now support a model in which mis-expression of the myotoxic DUX4 gene is a primary 
pathogenic event underlying FSHD.  We hypothesized that there was a direct correlation between 
DUX4 expression patterns and the involvement of only selected muscles (and ear and retinal 
pathologies) in FSHD.  In short, we proposed that if DUX4 over-expression is indeed an underlying 
pathogenic event in FSHD, it must be preferentially expressed in FSHD-affected regions.  To test this 
hypothesis, we developed transgenic reporter mice containing a putative DUX4 promoter cloned 
upstream of GFP.   We generated three separate lines ofDUX4 promoter-GFP mice.  We found the 
DUX4 promoter directed GFP expression in the face and limbs of newborn and adult mice, as well as 
the retina.  Essentially all other organs were GFP negative.  Strikingly, all lines showed asymmetrical 
expression and variable penetrance, even within individual litters.  We conclude that our mice 
faithfully recapitulate expected DUX4 expression patterns in regions of FSHD pathology, and further 
suggest the role of DUX4 as pathogenic insult in FSHD. 
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FSHD1 (OMIM 158900) is an AD disease affecting 1 in 20,000 and is the third most common form of 
muscular dystrophy, characterized by progressive wasting of upper body muscles. FSHD1 is associated 
with contraction of D4Z4 tandem repeat units in the subtelomere region 4q35. 
 
Bristol Genetics laboratory offers a UKGTN/international specialist diagnostic FSHD service. First line 
testing using the p13E-11 probe (to confirm the chromosome of origin and size of the D4Z4 
contraction), identifies 95% of individuals with FSHD. In 1-3% of the remaining cases a deletion of the 
D4Z4 repeat can extend proximally to include the p13E-11 probe site, giving a false-negative p13E-11 
result.  Reflex testing using MseI/EcoRI/BlnI digests and the D4Z4 probe (binds within the repeat array 
proper) allows the chromosome origin and number of D4Z4 repeats to be determined and is available 
for clinically typical FSHD patients, upon return of a clinical proforma.  
 
We present an audit of cases tested by D4Z4 analysis, and clinical information and results of extended 
analysis for a complex three generation FSHD family, with a deletion of the p13E-11 probe region. The 
index case presented with asymmetric proximal weakness, scapular winging and mild facial weakness; 
other relatives presented with variable phenotypes. Confirmation of an extended deletion facilitated 
urgent predictive testing related to pregnancy. This family illustrates the complexity and clinical utility 
of extended deletion analysis for FSHD. 
 
 
 
 
